Pharmaceutical Research & Manufacturers of America INC

Based in DC

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $9.3M in lobbying spend across 33 quarterly filings, Pharmaceutical Research & Manufacturers of America INC is one of the biggest lobbying spenders in Washington. They deploy 14 individual lobbyists Their lobbying covers 3 issue areas. Active from 2018 to 2025.

$9.3M
Total Spend
8
Years Active
1
Firms Hired
14
Lobbyists Deployed
3
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$1.2M
2019$1.7M
2020$1.2M
2021$1.4M
2022$1.3M
2023$630K
2024$980K
2025$940K

Issues Lobbied

Copyright/PatentHealth IssuesTrade

Lobbying Firms

Covington & Burling LLP

Lobbyists

Richard HertlingGabriel NevilleGary HeimbergJennifer ZacharyRichard KinghamKrista CarverThomas CosgroveJohn VeroneauLayth ElhassaniAndrew LazerowJennifer PlitschNatalie DerzkoMichael SternRobert Long

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Copyright/Patent, Health Issues, Trade

  • •Drug importation; Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Bayh-Dole march-in rights policy issues; Independent Payment Advisory Board - Protecting Seniors' Acce
  • •Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (H.R. 5247); Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327);
  • •Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Protecting Medicare from Executive Action Act of 2017 (S. 251); STRONGER Patents Act (S.1390); Medicare Part D coverage
  • •Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327); The Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act (i.e., the "SCREEN Act")(H.R. 52
  • •Part D/non-interference; Biopharmaceutical innovation and patent policy issues; Protecting Medicare from Executive Action Act of 2017 (S. 251); STRONGER Patents Act (S.1390)(HR 5340); Medicare Part D

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?
🏭 Tech Lobbying
Industry overview and top spenders
🏭 Pharma Lobbying
Industry overview and top spenders

Related Investigations

Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.

Similar Clients

Bayer Corporation (Consolidated Report)
$73.0M total spend
GSK (FKA Glaxosmithkline INC.)
$39.9M total spend
Siemens Healthineers (FKA Varian Medical Systems, INC.)
$1.9M total spend
Tiber Creek Health Strategies, INC. (on Behalf of Genentech, INC.)
$1.4M total spend
Association for Accessible Medicines (Formerly - Generic Pharmaceutical Assn)
$1.3M total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.